[Featured Stock] Cellivery, a Penny Stock That Plummeted, Drops 98% on First Day of Clearance Sale

Cellivery, a bio company that entered the KOSDAQ market as the country's first "growth special listing," has plunged to penny stock status as it began delisting liquidation trading on the 25th.

As of 9:40 a.m. that day, Cellivery's stock price was recorded at 153 won per share, down 97.71% compared to the closing price before the trading suspension. The opening price was also set at 100 won.

Cellivery's liquidation trading will proceed for seven trading days from that day until March 6. It is scheduled to be finally delisted on March 7. During the liquidation trading period, single-price trading will be conducted during regular hours (from 9 a.m. to 3:30 p.m.). There will be no price limit.

Cellivery was listed on the KOSDAQ in November 2018 through the growth special listing method. The growth special listing system is designed to relax listing requirements when a securities firm acts as the listing sponsor, allowing companies with high growth potential to go public (IPO).

In particular, leveraging its pharmacological substance in vivo delivery technology (TSDT), Cellivery once saw its stock price exceed 100,000 won as it pursued new drug development, including a treatment for Parkinson's disease. However, after receiving adverse audit opinions for two consecutive years, the KOSDAQ Market Committee decided on delisting last year. A provisional injunction to suspend the delisting decision was also recently dismissed. The founder and CEO, Cho Dae-woong, is currently under indictment and in custody on charges of violating the Capital Markets Act.

This content was produced with the assistance of AI translation services.